Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; pneumococcal conjugate vaccine; pneumococcal polysaccharide vaccine; immunization information system; sickle cell disease; ACIP; Advisory Committee on Immunization Practices; LBF; Live birth file; MCIR; Michigan Care Improvement Registry; MCV4; 4-Valent m
مقالات ISI واکسن پنوموکوک کاندیدای 13 ساعته (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-valent pneumococcal conjugate vaccine; Community-acquired pneumonia; Influenza virus; Viral community-acquired pneumonia; Viral pneumonia;
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Rheumatoid arthritis; Immunosuppressive therapy; 13-valent pneumococcal conjugate vaccine; Immunogenicity; Antibody persistence; RA; Rheumatoid arthritis patients; HC; Healthy control subjects; PnPS; pneumococcal polysaccharides; PCV13; 13-valent pneumoco
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; PPSV23; 23-valent pneumococcal polysaccharide vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; influenzavaccine; seasonal influenza vaccine; COPD; chronic obstructive pulmonary disease; ADL; activities of daily living; OR; odds ratio; CI; confide
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; HCPs; healthcare providers; VPDs; vaccine-preventable diseases; PCV13; 13-valent pneumococcal conjugate vaccine; Hib; Haemophilus influenzae type b; HBV; hepatitis B virus; DTaP; IPV-diphtheria, tetanus toxoid, acellular pertussis, and inactivated polio v
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; AE; adverse event; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; PCV7; 7-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; PHiD-CV; pn
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; AOM; acute otitis media; CI; confidence interval; CRM; cross-reacting material 197; DT; diphtheria toxoid; DTaP; diphtheria, tetanus, acellular pertussis; DTwP; diphtheria, tetanus, whole-cell pertussis; dPly; detoxified pneumolysin; EPA; exotoxin A of Ps
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Community-acquired pneumonia; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; ABC; Active Bacterial Core surveillance; ACIP; Advisory Committee on Immunization Practices; BAC; bacteremic; CAP; community acquired pn
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; ACIP; Advisory Committee on Immunization Practices; CAPiTA; Community-Acquired Pneumonia Immunization Trial in Adults; CPS; capsular polysaccharide; IPD; invasive pneumococcal disease; NIPP; noninvasive pneumococcal pneumonia; PCV7; 7-valent pneumococcal
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Idiopathic nephrotic syndrome (NS); Immunization; Streptococcus pneumoniae; 13-valent pneumococcal conjugate vaccine (PCV13); Vaccine; Enzyme-linked immunosorbent assay (ELISA); AIM; alternative immunosuppressive medication; CI; confidence interval; ELISA
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Pneumococcal polysaccharide vaccine; 23vPPV; hyporesponsiveness; memory BÂ cell; opsonophagocytosis; antibody; CPS; Cell-wall polysaccharide; FiPP; Fiji Pneumococcal Project; MOPA; Multiplexed opsonophagocytic assay; OI; Opsonization index; OPA; Opsonopha
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Pneumococcal conjugate vaccine; Vaccine clinical evaluation; Immunization; Immunogenicity; AE; adverse event; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; Ig; immunoglobulin; IPD; invasive pneumococ
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; AE; adverse event; CAP; community-acquired pneumonia; GMFR; geometric mean fold rise; GMT; geometric mean titer; IPD; invasive pneumococcal disease; OPA; opsonophagocytic activity; PCV13; 13-valent pneumococcal conjugate vaccine; PPSV23; 23-valent pneumoc
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; ARIa; cute respiratory infection; DSSd; emographic surveillance system; EPIe; xpanded program on immunization; GAVIg; lobal alliance for vaccines and immunization; IMCIi; ntegrated management of childhood illness; IPD; invasive pneumococcal disease; MEOm;
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; PCVs; pneumococcal conjugate vaccines; PCV7; 7-valent pneumococcal conjugate vaccine; PCV10; 10-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; Cost-effectiv
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Invasive pneumococcal disease; Pneumococcal pneumonia; Streptococcus pneumoniae; 7-Valent pneumococcal conjugate vaccine; 13-Valent pneumococcal conjugate vaccine; Adult vaccination;
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Streptococcus pneumoniae; Nasopharyngeal carriage; 7-Valent pneumococcal conjugate vaccine; 10-Valent pneumococcal conjugate vaccine; 13-Valent pneumococcal conjugate vaccine; Day-care centers;
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-Valent pneumococcal conjugate vaccine; Safety; Adverse events; Meta-analysis; Vaccination;
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; AE; adverse event; CI; confidence interval; CRM197; cross-reactive material 197; GMR; geometric mean ratio; GMT; geometric mean titer; IPD; invasive pneumococcal disease; LLOQ; lower limit of quantitation; LOD; limit of detection; OPA; opsonophagocytic ac
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; ACIP; United States Advisory Committee on Immunization Practices; AE; adverse event; CI; confidence interval; CRM197; cross-reactive material 197; GMR; geometric mean ratio; GMT; geometric mean titer; OPA; opsonophagocytic activity; PCV; pneumococcal poly
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15â¯months: A phase III, randomized, non-inferiority trial
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; MMR vaccine; Measles; Mumps; Rubella; Immunogenicity; Safety; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; HAV; hepatitis A
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults â¥50â¯years of age: A randomized trial
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; VZV; varicella-zoster virus; HZ; herpes zoster; PHN; postherpetic neuralgia; CDC; United States Centers for Disease Control and Prevention; YOA; years of age; ZVL; zoster vaccine live; RZV; adjuvanted recombinant zoster vaccine; PPSV23; 23-valent pneumoco
Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titre; hSBA; human complement serum bactericidal antibody assay; MenACWY-TT; quadrival
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV); 1-dose vial presentation; 4-dose vial presentation; Immunologic non-inferiority; Safety; Infants; AE; adverse event; ATP; according-to-protocol; CI; confidence interva
Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; PPSV23; 23-valent pneumococcal polysaccharide vaccine; IPD; invasive pneumococcal diseases; PCV13; 13-valent pneumococcal conjugate vaccine; OPA; opsonophagocytic assay; MOPA; multiplexed OPA; OBB; opsonization buffer B; BRC; Baby rabbit complement; THY;
PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend?
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Streptococcus pneumoniae; Serotypes; Adults; Invasive pneumococcal disease; 13-Valent pneumococcal conjugate vaccine; Herd protection;
Memory B cell response to a PCV-13 booster in 3.5Â year old children primed with either PCV-7 or PCV-13
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; ASC; antibody secreting cells; BCR; B cell receptor; BMEM; memory B cells; GC; germinal centre; LLD; lower limit of detection; MenC; group C meningococcus; OPA; opsonophagocytic activity; PBMCs; peripheral blood mononuclear cells; PBS; phosphate buffered
Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; ACIP; Advisory Committee on Immunization Practices; ANOVA; analysis of variance; ART; antiretroviral therapy; BAFF-R; B cell-activating factor receptor; CBC; complete blood count; CD4; CD4+ T cells/μl; HIV; human immunodeficiency virus; Ig; immunoglobuli
Bacteremic Pneumonia before and after Withdrawal of 13-Valent Pneumococcal Conjugate Vaccine from a Public Vaccination Program in Spain: A Case-Control Study
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; CAP; Community-acquired pneumonia; IPD; Invasive pneumococcal disease; PCV13; 13-valent pneumococcal conjugate vaccine; PCV7; 7-valent pneumococcal conjugate vaccine; WBC; White blood cell;
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; aIIV3; adjuvanted trivalent inactivated influenza vaccine; IIV3; inactivated trivalent influenza vaccine; PPSV23; 23-valent pneumococcal polysaccharide vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; HI; hemagglutination inhibition; GMT; geometr
Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; PHiD-CV; 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; NIP; National Immunization Program; PCV7; 7-valent pneumococcal conjugate vaccine; IPD; Invasive pneumococcal disease; PCV13; 13-valent pneumococcal conjugate
Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-Valent pneumococcal conjugate vaccine; Otitis media; Bacteriology
The incidence of pediatric invasive Haemophilus influenzae and pneumococcal disease in Chiba prefecture, Japan before and after the introduction of conjugate vaccines
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Hib; Haemophilus influenzae type b; PCV7; heptavalent pneumococcal conjugate vaccine; IPD; invasive pneumococcal disease; PCV13; 13-valent pneumococcal conjugate vaccine; IHiD; invasive Haemophilus influenzae disease; IRR; incidence rate ratio; CI; confid
Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; cost-effectiveness; Malaysia; nontypeable Haemophilus influenzae; PHiD-CV; pneumococcal conjugate vaccine; pneumococcal protein-D conjugate vaccine; Streptococcus pneumoniae; 13-valent pneumococcal conjugate vaccine;
Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged â¥65 years
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-Valent pneumococcal conjugate vaccine; Trivalent inactivated influenza vaccine; Opsonophagocytic activity; Noninferiority;
Sampling methods for the study of pneumococcal carriage: A systematic review
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; STGG; skim milk-trypton-glucose-glycerin; SGG; skim milk-glycerol-glucose; ETA; egg-thioglycolate-antibiotic media; PCR; polymerase chain reaction; WHO; World Health Organisation; PCV-7; 7-valent pneumococcal conjugate vaccine; PCV-13; 13-valent pneumococ
Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; CI; confidence interval; IPD; invasive pneumococcal disease; NVT; non-vaccine serotype; NVT-IPD; non-vaccine serotype invasive pneumococcal disease; NVT-PM; non-vaccine serotype pneumococcal meningitis; PM; pneumococcal meningitis; PCV7; 7-valent pneumoco
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjuga
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-valent pneumococcal conjugate vaccine; Pneumococcal vaccination; Infants
Pneumococcal vaccination in adults: Does it really work?
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Pneumococcus; Vaccine; Polysaccharide; Conjugate; Efficacy; CAP; Community acquired pneumonia; PPV; Pneumococcal polysaccharide vaccine; PPV23; 23-valent pneumococcal polysaccharide vaccine; PCV; Pneumococcal conjugate vaccine; PCV7; 7-valent pneumococcal
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged â¥65 years
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-Valent pneumococcal conjugate vaccine; Europe; Immunogenicity; Safety;
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Safety; Immunogenicity; 13-Valent pneumococcal conjugate vaccine; 7-Valent pneumococcal conjugate vaccine; Toddler dose; Infants;
The potential cost-effectiveness of infant pneumococcal vaccines in Australia
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 3Â +Â 0; vaccine dose schedule of 3 infant doses without toddler booster dose; 3Â +Â 1; vaccine dose schedule of 3 infant doses and one toddler dose; AIHW; Australian Institute of Health and Welfare; AR-DRG; Australian refined-diagnosis related group; BEA
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; 13-Valent pneumococcal conjugate vaccine; Pneumococcal vaccination; Infants
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
Keywords: واکسن پنوموکوک کاندیدای 13 ساعته; Safety; Immunogenicity; 13-valent pneumococcal conjugate vaccine